Functional Study of the Retrotransposon-Derived Human PEG10 Protease is a research paper published in International Journal of Molecular Sciences (2020). On theSindex it has a DataRank of 0. It has been cited 41 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
GINOP
Grant: GINOP-2.3.2-15-2016-00044 “PHARMPROT teaming”
NKFIH
Grant: NKFIH-1150-6/2019
OTKA
Grant: K-101591
NKFI
Grant: NKFI-125238
GINOP
Grant: GINOP-2.3.2-15-2016-00044 "PHARMPROT teaming"
FWCI
2.89
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 1 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 2 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 2 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 3 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 3 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 4 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 4 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 5 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 5 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 6 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 6 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 7 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 7 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 8 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Additional file 8 of Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer